Conference Coverage

Enhanced education, customized follow-up options improve STD retesting rates


 

AT THE 2014 STD PREVENTION CONFERENCE

References

ATLANTA – Educating patients treated for chlamydia or gonorrhea about reinfection and retesting, and providing customized options for follow-up care, increased patient retest return rates by 15% in a prospective cohort study.

The return rate at 1-6 months after treatment among 1,454 patients who received enhanced educational information about reinfection and the importance of retesting during the first phase of the InTOUCH study was 59%, and the return rate among 575 patients who received that educational information along with customized reminders and/or a mailed-in home testing kit in a second phase was 62%, compared with a return rate of 54% among 2,696 historical controls, Holly Howard reported at a conference on STD prevention sponsored by the Centers for Disease Control and Prevention.

The increases in return rates were statistically significant, said Ms. Howard of the California Department of Public Health, Richmond.

The initial education phase of the multicenter study occurred in 2010 and 2011 at six geographically diverse California Title X clinics. Participants were clients of the California Family Planning, Access, Care, and Treatment Program, which provides care to more than 2 million low-income women each year.

The patients were counseled about the risks and dangers of re-infection and the importance of retesting, and were given tips for remembering to return for retesting. Additionally, educational materials were updated to improve readability and user friendliness.

During 2011 and 2012, patients from the educational phase who tested positive for chlamydia or gonorrhea, and who were treated for the infections, were officially enrolled in the second phase of the study, during which they were offered the option of receiving retest reminders via postcard, text, and/or e-mail, as well as the option of retesting with a home test sent to their address 3 months after treatment.

Most patients (90%) opted to receive retest reminders, and most of those chose text and e-mail reminders. Only 5% chose to use the home test kit.

Pages

Recommended Reading

HIV screening: How we can do better
MDedge Family Medicine
CDC panel: For children, live attenuated intranasal flu vaccine is best
MDedge Family Medicine
Shifting our focus to HIV as a chronic disease
MDedge Family Medicine
CDC okays group meningitis vaccination in emergency
MDedge Family Medicine
High gonorrhea reinfection rate underscores need for rescreening
MDedge Family Medicine
New York’s ambitious agenda seeks to end the HIV epidemic
MDedge Family Medicine
Rotavirus vaccine saved an estimated $924 million in 4 years
MDedge Family Medicine
Debate continues on antibiotic prophylaxis for UTIs in children with reflux
MDedge Family Medicine
New Pap testing recommendations raise concerns about prenatal STD screening
MDedge Family Medicine
Measles & pertussis: How best to respond to an outbreak
MDedge Family Medicine